Overview |
bs-12462R |
AGPS/Alkyl-DHAP synthase Antibody |
ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
Rat |
Human, Mouse, Cow, Pig, Horse |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human AGPS/Alkyl-DHAP synthase |
31-130/658 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
8540 |
Cytoplasm, Cell membrane |
AAG5; ADAP-S; ADAS; ADAS_HUMAN; ADHAPS; ADPS; Aging associated gene 5 protein; Aging-associated gene 5 protein; AGPS; ALDHPSY; Alkyl-DHAP synthase; Alkyldihydroxyacetonephosphate synthase; Alkyldihydroxyacetonephosphate synthase, peroxisomal; Alkylglycerone phosphate synthase; Alkylglycerone-phosphate synthase; peroxisomal. |
AGPS is a 658 amino acid enzyme that is required for glycerolipid metabolism and ether lipid biosynthesis. Localized to the inner aspect of the peroxisomal membrane, AGPS is likely part of a heterotrimeric complex that is also composed of GNPAT and a modified form of GNPAT. Containing one FAD-binding PCMH-type domain, AGPS utilizes FAD as a cofactor in the synthesis of alkyl-glycerone 3-phophate and a long-chain acid anion from 1-acteyl-glyerone 3-phosphate and a long-chain alcohol. Defects in the gene encoding AGPS results in rhizomelic chondrodysplasia punctata type 3, a disease characterized by vertebral disorders, severe mental retardation, cutaneous lesions, cataracts and rhizomelic shortening of the humerus and femur. |
Application Dilution |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |